Abstract:Highlights • Synergistic Immune Activation: The sustained release of CDDP and DAC triggers Gasdermin E (GSDME)-mediated pyroptosis, which activates the adaptive immune response, while Mn 2+ enhances the activation of innate immunity through the STING pathway. • Significant Anti-Tumor Effects: The immunogel has shown encouraging anti-tumor effects, with an 80 % total survival rate for recurrent tumors and a 60 % survival rate for metastatic tumors. • Simplicity in Formulation and Preparation: The formulation of the immunogel is simple, and the preparation method is easy to handle, offering a promising strategy for postoperative cancer therapy. Tumor recurrence and metastasis after surgery are important factors affecting patient survival. The immunosuppressed tumor microenvironment after surgery reduces the ability of the immune system to clear residual tumor cells, thus increasing the risk of recurrence and metastasis. Currently, immunotherapy-based adjuvant therapy can effectively inhibit tumor recurrence and metastasis after surgery, but simultaneous and efficient synergistic activation of adaptive and innate immunity is a challenge. Here, we utilized polymeric hydrogel loaded with decitabine (DAC), cisplatin (CDDP) and manganese ions (Mn 2+ ) as a postoperative filler immunogel to synergistically activate both anti-tumor innate and adaptive immunity. The sustained release of CDDP and DAC burst gasdermin E (GSDME)-mediated pyroptosis and activated adaptive immunity, while Mn 2+ enhanced intrinsic immune activation through STING pathway. Such immunogel achieved an encouraging anti-tumor effect with an 80 % total survival rate for recurrent tumors and a 60 % survival rate for metastatic tumors. Considering that this in situ immunogel possesses simple formulation and displays superior anti-tumor effect, this research provided a promising strategy for postoperative cancer therapy. Graphical abstract After surgery, a suppressed immune system increases the risk of tumor recurrence and metastasis. The novel immunogel in our study, a polymer hydrogel with pyroptosis inducers and adjuvants, works synergistically to enhance anti-tumor immunity and achieve survival rates of 80 % for recurrence and 60 % for metastasis. Download: Download high-res image (411KB) Download: Download full-size image

Unified Therapeutic‐Prophylactic Vaccine Demonstrated with a Postoperative Filler Gel to Prevent Tumor Recurrence and Metastasis

A Cancer Vaccine-Mediated Postoperative Immunotherapy for Recurrent and Metastatic Tumors.

Tumor Microenvironment‐Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade‐Amplified Immune Response against Tumor Growth, Metastasis and Recurrence

Polymeric immunogel prevents tumor recurrence and metastasis by dual activation of innate and adaptive immunity

The Ectopic Expression of Survivin T34A and FilC Can Enhance the Oncolytic Effects of Vaccinia Virus in Murine Gastric Cancer

Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination

A laponite-based immunologically active gel delivery system for long-acting tumor vaccine

In Situ Tumor Vaccine with Optimized Nanoadjuvants and Lymph Node Targeting Capacity to Treat Ovarian Cancer and Metastases

Macrophage-derived implantable vaccine prevents postsurgical tumor recurrence

Programming of in Situ Tumor Vaccines via Supramolecular Nanodrug/Hydrogel Composite and Deformable Nanoadjuvant for Cancer Immunotherapy

Immunogenicity and Efficacy of a Rationally Designed Vaccine Against Vascular Endothelial Growth Factor in Mouse Solid Tumor Models

A tumor-to-lymph procedure navigated versatile gel system for combinatorial therapy against tumor recurrence and metastasis

Immunotherapeutic Hydrogel with Photothermal Induced Immunogenic Cell Death and STING Activation for Post‐Surgical Treatment

In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment

An Ultrasound‐Responsive and In Situ Gelling Hydrogel Nanocomposite for Boosting Anti PD‐L1 Immunotherapy via Remodeling Aberrant ECM of Post‐Surgical Residual Cancer

I n situ tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity to treat ovarian cancer and metastases

A single-shot prophylactic tumor vaccine enabled by an injectable biomembrane hydrogel

Exploiting Immunostimulatory Mechanisms of Immunogenic Cell Death to Develop Membrane-Encapsulated Nanoparticles As a Potent Tumor Vaccine.

Bis-2'-F-cGSASMP isomers encapsulated in cytidinyl/cationic lipids act as potent in situ autologous tumor vaccines

Protective Antitumor Immunity Induced by Tumor Cell Lysates Conjugated with Diphtheria Toxin and Adjuvant Epitope in Mouse Breast Tumor Models

Postsurgical wound management and prevention of triple-negative breast cancer recurrence with a pryoptosis-inducing, photopolymerizable hydrogel